• OPEN AN ACCOUNT
Indian Indices
Nifty
22,442.70 -33.15
(-0.15%)
Sensex
73,895.54 17.39
( 0.02%)
Bank Nifty
48,895.30 -28.25
( -0.06%)
Nifty IT
33,217.15 308.75
( 0.94%)
Global Indices
Nasdaq
16,156.33 315.37
(1.99%)
Dow Jones
38,675.68 450.02
(1.18%)
Hang Seng
18,578.30 102.38
(0.55%)
Nikkei 225
38,236.07 -37.98
(-0.10%)
Forex
USD-INR
83.43 -0.03
(-0.04%)
EUR-INR
89.37 0.26
(0.29%)
GBP-INR
104.48 0.21
(0.20%)
JPY-INR
0.54 0.01
(1.69%)

EQUITY - MARKET SCREENER

Eastern Sugar & Industries Ltd
Industry :  Sugar
BSE Code
ISIN Demat
Book Value()
507528
INE889B01016
14.8839627
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EASTSUGIND
0
3.15
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Laurus Labs’ Andhra Pradesh facility clears USFDA inspection
Apr 20,2024
The inspection was conducted from 15th April, 2024 to 19th April, 2024. The said inspection was closed with zero 483 observations.

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral, oncology drugs, cardiovascular, gastro and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations, provide contract research and manufacturing services (CRAMS) to global pharma companies.

The company’s consolidated net profit dropped 88.6% to Rs 23.14 crore on 22.65% decrease in revenue from operations to Rs 1,544.82 crore in Q3 FY24 over Q3 FY23.

The scrip fell 1.26% to end at Rs 426.25 on Friday, 19 April 2024.